India-based global pharmaceutical company Lupin Limited (BSE: 500257; NSE: LUPIN; REUTERS: LUPIN.BO; BLOOMBERG: LPCIN) announced on Monday that it has received the final approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.
The US FDA has approved Lupin's Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labelling.
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Aurisco Pharmaceutical reports successful US FDA inspection
Galvanize Therapeutics' new Aliya EX System completes first commercial procedures
Lupin's Sodium Zirconium Cyclosilicate for Oral Suspension approved by US FDA
Labcorp receives FDA approval for melanoma companion diagnostic
Sobi partners with Innate Pharma to advance lacutamab in T-cell lymphoma